Ginwa Enterprise Group Inc
SSE:600080

Watchlist Manager
Ginwa Enterprise Group Inc Logo
Ginwa Enterprise Group Inc
SSE:600080
Watchlist
Price: 7.65 CNY 0.79% Market Closed
Market Cap: 2.9B CNY

Relative Value

The Relative Value of one Ginwa Enterprise Group Inc stock under the Base Case scenario is 4.22 CNY. Compared to the current market price of 7.65 CNY, Ginwa Enterprise Group Inc is Overvalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4.22 CNY
Overvaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
22
vs Industry
26
Median 3Y
4.8
Median 5Y
4.8
Industry
2.6
vs History
55
vs Industry
0
Median 3Y
37
Median 5Y
37.5
Industry
21.4
vs History
vs Industry
11
Median 3Y
36.2
Median 5Y
44.2
Industry
16.4
vs History
vs Industry
32
Median 3Y
-12.8
Median 5Y
-12
Industry
22.8
vs History
19
vs Industry
40
Median 3Y
1.7
Median 5Y
1.7
Industry
2.2
vs History
3
vs Industry
27
Median 3Y
4.1
Median 5Y
4
Industry
2.9
vs History
3
vs Industry
35
Median 3Y
5.4
Median 5Y
5.3
Industry
5.5
vs History
46
vs Industry
0
Median 3Y
155.3
Median 5Y
155.3
Industry
13
vs History
46
vs Industry
1
Median 3Y
155.3
Median 5Y
155.3
Industry
16.5
vs History
vs Industry
12
Median 3Y
30.8
Median 5Y
34.5
Industry
15.6
vs History
vs Industry
33
Median 3Y
-11.3
Median 5Y
-9.4
Industry
18.7
vs History
69
vs Industry
39
Median 3Y
1.6
Median 5Y
1.6
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Ginwa Enterprise Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Ginwa Enterprise Group Inc
SSE:600080
2.9B CNY 5.2 36.4 159.9 159.9
US
Eli Lilly and Co
NYSE:LLY
997.6B USD 16.8 54.2 36.4 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.8B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
263.6B CHF 4.3 28 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
218.4B GBP 5.1 31.5 109.5 160.2
CH
Novartis AG
SIX:NOVN
214.5B CHF 4.8 18.8 11.9 15.4
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 11 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
CN
Ginwa Enterprise Group Inc
SSE:600080
Average P/E: 25.9
36.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Ginwa Enterprise Group Inc
SSE:600080
Average EV/EBITDA: 414.5
159.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.5
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Ginwa Enterprise Group Inc
SSE:600080
Average EV/EBIT: 1 726.9
159.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
160.2
23%
7
CH
Novartis AG
SIX:NOVN
15.4
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5